首页> 外文期刊>Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy >Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia?
【24h】

Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia?

机译:血液透析相关性肺炎(HDAP)的临床和微生物学评估:HDAP是否应包括在医疗保健相关性肺炎中?

获取原文
获取原文并翻译 | 示例
           

摘要

Although hemodialysis-associated pneumonia (HDAP) was included among the healthcare-associated pneumonias (HCAP) in the 2005 American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guideline, little information relevant to clinical epidemiology, especially microbiological characteristics, is available. This study aimed to reveal microbiological characteristics and clinical outcomes of HDAP and to assess whether HDAP should be included in the HCAP category. We retrospectively analyzed 69 HDAP patients [42 with moderate and 27 with severe disease based on A-DROP (age, dehydration, respiratory failure, orientation disturbance, and low blood pressure)] in whom sputum cultures were performed at our hospital between 2007 and 2009. The most common pathogens were Staphylococcus aureus (37.7%), which were composed of methicillin-resistant S. aureus (MRSA) (27.5%) and methicillin-sensitive S. aureus (MSSA) (10.1%), followed by Streptococcus pneumoniae (10.1%), Klebsiella pneumoniae (8.7%), Haemophilus influenzae (7.2%), and Moraxella catarrhalis (5.8%). This distribution mostly resembled the microbiological characteristics of HCAP reported previously, except that the frequency of multi-drug-resistant (MDR) gram negatives such as Pseudomonas aeruginosa (2.9%) was clearly lower and that of MRSA was higher. There were no significant differences in microbiological findings, including the incidence of MDR pathogens, between the two severity groups. Despite most cases (82.6%) receiving only monotherapy, the prognosis (30-day survival and in-hospital mortality rates were 88.4% and, 17.4%, respectively) was similar to the past HCAP reports, but there were no significant correlations between prognosis and presence of MDR pathogens (30-day mortality rates 18.2% in MDR positive vs. 8.5% in MDR negative; p = 0.242). Assessment for not only MDR pathogens, but also severity of illness by the A-DROP system made it possible to conduct stratification based on prognosis. Our results suggest that HDAP should be included in the HCAP category, while understanding that there are some differences.
机译:尽管在2005年美国胸科学会(ATS)/美国传染病学会(IDSA)指南中将血液透析相关性肺炎(HDAP)纳入了医疗保健相关性肺炎(HCAP),但与临床流行病学(尤其是微生物学特征)相关的信息很少,可用。这项研究旨在揭示HDAP的微生物学特征和临床结果,并评估HDAP是否应包括在HCAP类别中。我们回顾性分析了2007年至2009年间在我院进行痰培养的69例HDAP患者[42例中度和27例基于A-DROP(年龄,脱水,呼吸衰竭,取向障碍和低血压)的严重疾病]。 。最常见的病原体是金黄色葡萄球菌(37.7%),由耐甲氧西林的金黄色葡萄球菌(MRSA)(27.5%)和耐甲氧西林的金黄色葡萄球菌(MSSA)(10.1%)组成,其次是肺炎链球菌( 10.1%),肺炎克雷伯菌(8.7%),流感嗜血杆菌(7.2%)和卡他莫拉菌(5.8%)。该分布与以前报道的HCAP的微生物学特征非常相似,只是铜绿假单胞菌等多重耐药(MDR)革兰氏阴性的频率(2.9%)明显较低,而MRSA的频率较高。在两个严重程度组之间,微生物学发现(包括MDR病原体的发生率)没有显着差异。尽管大多数病例(82.6%)仅接受单药治疗,但其预后(30天生存率和院内死亡率分别为88.4%和17.4%)与以往的HCAP报告相似,但预后之间无显着相关性。以及MDR病原体的存在(MDR阳性的30天死亡率为18.2%,MDR阴性的为30%死亡率; p = 0.242)。通过A-DROP系统不仅可以评估MDR病原体,还可以评估疾病的严重程度,从而有可能根据预后进行分层。我们的结果表明,HDAP应该包含在HCAP类别中,同时要了解存在一些差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号